Session » Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I

Date: Sunday, November 13, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 606

A Randomized, Double Blind, Single Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of ONS-3010 (Adalimumab, Oncobiologics, Inc.) Compared to Two Reference Products of Humira® (AbbVie) in Healthy Adult Subjects

9:00AM-11:00AM: Abstract Number: 638

A Randomized, Open-Label, Single-Dose, Parallel-Group Trial to Determine the Pharmacokinetics, Safety and Immunogenicity of GP2017, a Proposed Adalimumab Biosimilar, Following a Single Subcutaneous Injection By an Autoinjector or Prefilled Syringe in Healthy Male Subjects

9:00AM-11:00AM: Abstract Number: 610

A Systematic Review and Meta-Analysis of Comparative Efficacy of Biologics in Treating Patients with Rheumatoid Arthritis: Assessment of Long-Term Radiographic Progression from Published Clinical Trials

9:00AM-11:00AM: Abstract Number: 616

ABP 501 Long-Term Safety/Efficacy: Interim Results from an Open-Label Extension Study

9:00AM-11:00AM: Abstract Number: 650

ABT-122, a Tnf– and IL-17–Targeted Dual Variable Domain (DVD)–Ig™ in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results from a Phase 2 Trial

9:00AM-11:00AM: Abstract Number: 648

ABT-122, an Anti-TNF/Anti-IL-17 Dual Variable Domain Antibody, Alters T Cell Responses in Human Subjects

9:00AM-11:00AM: Abstract Number: 593

Adalimumab (HUMIRA) Halts Radiographic Progression and Reduces Disease Activity in Patients with a Poor Initial Response to Methotrexate

9:00AM-11:00AM: Abstract Number: 603

Additional Efficacy Results of SB4 (Etanercept Biosimilar) up to Week 100: Comparison Between Continuing SB4 and Switching from Reference Etanercept (Enbrel®) to SB4

9:00AM-11:00AM: Abstract Number: 598

An Assessment of the Correlation Between Gender and Anticipated Drug Retention to TNF Inhibitors: A Meta-Regression Analysis

9:00AM-11:00AM: Abstract Number: 611

Analysis of a German Subpopulation with Active Rheumatoid Arthritis Treated with Golimumab As Add-on Therapy to Disease-Modifying Antirheumatic Drugs

9:00AM-11:00AM: Abstract Number: 628

Analysis of Baseline Characteristics of Rheumatoid Arthritis Patients Treated with Abatacept Compared to Those Treated with Tumor Necrosis Factor Inhibitors in Clinical Practice

9:00AM-11:00AM: Abstract Number: 605

Assessment of Comparative Immunogenicity in Biosimilar Development: Immunogenicity and Pharmacokinetics Following a Single Dose of M923, a Proposed Biosimilar for Reference Adalimumab (HUMIRA®), Compared with US- and EU-Sourced Reference Adalimumab in Healthy Subjects

9:00AM-11:00AM: Abstract Number: 624

Association Between Methotrexate Use and Effects of Treatment with a Second Biologic Agent in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 596

Association Between Plasma Certolizumab Pegol Concentration and Improvement in Disease Activity in Rheumatoid Arthritis and Crohn’s Disease

9:00AM-11:00AM: Abstract Number: 631

Biologic Free Remission Rate with Etanercept in Rheumatoid Arthritis: A Potential Role of Gender

9:00AM-11:00AM: Abstract Number: 637

Biologic Initiation Patterns Among Rheumatoid Arthritis Patients in Moderate or High Disease Activity While Using Conventional Disease Modifying Anti-Rheumatic Drugs

9:00AM-11:00AM: Abstract Number: 651

Calprotectin Serum Levels Strongly Predict Disease Flare in RA and Psa Patients with Low Disease Activity Treated with TNF Inhibitors. a One-Year Prospective Cohort Study

9:00AM-11:00AM: Abstract Number: 614

Canadian Study of Outcomes in Adalimumab (HUMIRA®) Patients with Support for Adherence – Results from the Companion Study

9:00AM-11:00AM: Abstract Number: 595

Cinical Responses and Improvements in Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol

9:00AM-11:00AM: Abstract Number: 620

Clinical Activity, Ultrasound Assessment and Drug Monitoring in Rheumatoid Arthritis Patients Receiving Anti-TNF-α Therapy with Extended Interval of Administration

9:00AM-11:00AM: Abstract Number: 627

Clinical and Immunogenicity Outcomes after Switching Treatment from Innovator Infliximab to Biosimilar Infliximab in Rheumatic Diseases in Daily Clinical Practice

9:00AM-11:00AM: Abstract Number: 649

Clinical Evaluation Usefulness of Standardized Protocol Strategies of Dose Reduction in Patients with Rheumatoid Arthritis in Clinical Remission Treated with Biologic Therapies. the Optibio Study

9:00AM-11:00AM: Abstract Number: 640

Clinical Responses and Synovial Vascularity in Obese Rheumatoid Arthritis Patients Treated with Adalimumab and Methotrexate

9:00AM-11:00AM: Abstract Number: 597

Comparative Effectiveness of Different Anti-TNF Drugs As First Biological DMARD in RA: Results from the Nationwide Swedish Register 2010-2015

9:00AM-11:00AM: Abstract Number: 632

Comparative Improvement in Health-Related Quality of Life for RA Patients Between TNF-α Inhibitors, Other Biologics, and Tofacitinib: Results from a US-Wide Observational Study

9:00AM-11:00AM: Abstract Number: 619

Concomitant Treatment Use during Treatment with Golimumab in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 601

Differing Contribution of Methotrexate Polyglutamation to Infliximab and Adalimumab Exposure As Compared to Etanercept

9:00AM-11:00AM: Abstract Number: 600

Disease Activity Trends after Dose Escalation of Infliximab (Remicade) – Results from United States Consortium of Rheumatology Researchers of North America Registry

9:00AM-11:00AM: Abstract Number: 618

Do Canadian Rheumatologists Actually Treat to Target Once a Biologic Has Been Initiated? an Analysis from a Prospective, Observational Registry

9:00AM-11:00AM: Abstract Number: 609

Economic Impact of Adalimumab Treatment in Japanese Patients with Rheumatoid Arthritis from the Anouveau Study (Clinicaltrial.gov: NCT01346488)

9:00AM-11:00AM: Abstract Number: 621

Effectiveness and Safety of CT- P13 (Biosimilar Reference Infliximab) in a Real-Life Setting in 151 Patients with Rheumatoid Arthritis and Ankylosing Spondylitis: A Mid-Term Interim Analysis

9:00AM-11:00AM: Abstract Number: 622

Efficacy after Transition to SB5 from Reference Adalimumab (Humira®) Vs. Continuation of SB5 or Reference Adalimumab By Antibodies Developed after Transition from a SB5 Phase III Study

9:00AM-11:00AM: Abstract Number: 625

Efficacy and Safety of Intravenous Golimumab Plus Methotrexate in Patients 65 Years and Younger and Those Greater Than 65 Years of Age-a Post-Hoc Analysis

9:00AM-11:00AM: Abstract Number: 602

Efficacy and Safety of Switching Between Certolizumab Pegol and Adalimumab after Primary Anti-TNF Treatment Failure: 2-Year Results from a Randomized, Investigator-Blind, Superiority Head-to-Head Study

9:00AM-11:00AM: Abstract Number: 643

Exposure-Response Analyses of Efficacy of ABT-122, a Dual-Variable Domain Immunoglobulin (DVD-Ig™) Targeting TNF-α and IL-17A, Compared with Adalimumab in Subjects with Rheumatoid Arthritis and Background MTX

9:00AM-11:00AM: Abstract Number: 635

Factors Associated to Lack of Adherence to Subcutaneous Biological Medications in Patients with Rheumatoid Arthritis from Spain. Arco Study

9:00AM-11:00AM: Abstract Number: 647

Genomic and Epigenetic Bioinformatics Demonstrate Dual TNF-α and IL17A Target Engagement By ABT-122, and Suggest Mainly TNF-α–Mediated Relative Target Contribution to Drug Response in MTX-IR Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 629

Golimumab Improves Patient-Reported Outcomes and Socio- and Health-Economic Parameters in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS): Results from a Non-Interventional Clinical Evaluation in Germany

9:00AM-11:00AM: Abstract Number: 633

High Similarity Between Ex-Vivo Inhibited Cytokine Profiling By Golimumab and Adalimumab As a Putative Explanation for Inferior Treatment Response to Golimumab after Adalimumab Failure in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 613

Immunogenicity of Anti-TNF Therapies in Patients with Inflammatory Rheumatic Diseases and Secondary Failure: A Multicentre Study of 570 Patients

9:00AM-11:00AM: Abstract Number: 592

Impact of Adherence to Tumor Necrosis Factor Inhibitors on Radiographic Outcomes in US Veterans with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 608

Initial Intensive Therapy of Adalimumab and Methotrexate Is Associated with Long-Term Structural Remission and Low Disease Activity after Adalimumab Discontinuation Is Maintained up to 3 Years in Japanese Patients: Hopeful-3 Study

9:00AM-11:00AM: Abstract Number: 612

Long-Term Sustainability of TNF-Blocker Injection Spacing in Rheumatoid Arthritis: Results of a 3-Year Long-Term Observational Follow-up of a Tapering randomised Controlled Trial

9:00AM-11:00AM: Abstract Number: 594

Maintenance of Improvements in Patients’ Physical Function, Workplace and Household Productivity, and Reduction in Caregiver Burden with 2 Years of Certolizumab Pegol Treatment in DMARD-Naive, Early RA Patients with Severe Progressive Disease

9:00AM-11:00AM: Abstract Number: 591

Patient-Reported Outcomes for Etanercept Therapy in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment

9:00AM-11:00AM: Abstract Number: 615

Pharmacokinetic Similarity of ABP 710 Relative to Infliximab: Results from a Randomized, Single-Blind, Single-Dose, Parallel Group Study in Healthy Subjects

9:00AM-11:00AM: Abstract Number: 646

Population Pharmacokinetics of ABT-122, an Immunoglobulin Targeting Both TNF-α and IL-17A: Analyses Across Phase 1 Studies in Healthy Volunteers and Phase 2 Studies in Subjects with Rheumatoid or Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 645

Prospective Observational Real-Life Study (STRATEGE) Shows the Efficacy of Treat-to-Target Strategy and Methotrexate Monotherapy Optimization in Patients with Established Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 636

Prospective, Intervention, Multicenter Study of Utility of Biologic Drug Monitoring with Respect to the Efficacy and Cost of Adalimumab Tapering in Patients with Rheumatic Diseases (34-week descriptive data)

9:00AM-11:00AM: Abstract Number: 642

Quality of Life Outcomes Following Therapy with Chs-0214 and Etanercept (Enbrel): Randomized, Double-Blind Study in Subjects with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 599

Real World United States-Based Clinical Experience with Prior Biologic Use Among First Time Golimumab Intravenous and Infliximab Treated Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 641

Reduction of Concomitant Oral Methotrexate or Corticosteroids in Combination Treatment with Adalimumab Does Not Affect Effectiveness in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 644

Seroprevalence and Its Impact on Radiographic Damage in Korean Rheumatoid Arthritis Patients Starting Biologics

9:00AM-11:00AM: Abstract Number: 630

Strategies for Biological Drug Quantification in Biological Drug Immune Responses

9:00AM-11:00AM: Abstract Number: 604

Sustained Efficacy and Comparable Safety and Immunogenicity after Transition to SB5 (an Adalimumab Biosimilar) Vs. Continuation of SB5 or Reference Adalimumab (Humira®) in Patients with Rheumatoid Arthritis: Results of Phase III Study

9:00AM-11:00AM: Abstract Number: 626

Switching Biologic Therapy in a Population of Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 639

Switching to Biosimilars in Rheumatology: Evidence-Based Practice

9:00AM-11:00AM: Abstract Number: 607

The Clinical Response to Biologic and Non-Biologic Disease Modifying Antirheumatic Drugs (DMARDs) According to Gender in a French-Canadian Population with Rheumatoid Arthritis (RA)

9:00AM-11:00AM: Abstract Number: 652

The Reasons for Discontinuation of Combination Therapy with Methotrexate and Tumor Necrosis Factor Inhibitors Versus Triple Therapy Differ Significantly Because of Higher Adverse Events with Triple Therapy

9:00AM-11:00AM: Abstract Number: 617

Therapy in Patients with Rheumatoid Arthritis (RA) with Inadequate Response to Tumor Necrosis Factor Alpha Inhibitors (TNFi): A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs

9:00AM-11:00AM: Abstract Number: 634

Use of Biosimilars in Clinical Practice: A Swedish National Register-Based Assessment

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].